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Abstract
AIM: To study the efficacy, safety, and feasibility of a 
granulocyte adsorptive type apheresis system for the 
treatment of patients with chronically active ulcerative 
colitis despite standard therapy.
METHODS: An open label multicenter study was carried 
out in 39 patients with active ulcerative colitis (CAI 
6-8) despite continuous use of steroids (a minimum 
total dose of 400 mg prednisone within the last 4 wk). 
Patients received a total of five aphereses using a 
granulocyte adsorptive technique (Adacolumn®, Otsuka 
Pharmaceutical Europe, UK). Assessments at wk 6 and 
during follow-up until 4 mo comprised clinical (CAI) and 
endoscopic (EI) activity index, histology, quality of life 
(IBDQ), and laboratory tests. 
RESULTS: Thirty-five out of thirty-nine patients were 
qualified for intent-to-treat analysis. After the apheresis 
treatment at wk 6, 13/35 (37.1%) patients achieved 
clinical remission and 10/35 (28.6%) patients had 
endoscopic remission (CAI<4, EI<4). Quality of life 
(IBDQ) increased significantly (24 points, P <0.01) 
at wk 6. Apheresis could be performed in all but one 
patient. Aphereses were well tolerated, only one patient 
experienced anemia. 
CONCLUSION: In patients with steroid refractory 
ulcerative colitis, five aphereses with a granulocyte/
monocyte depleting filter show potential short-term 
efficacy. Tolerability and technical feasibility of the 
procedure are excellent.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Systemically acting corticosteroids are mainstay in the 
treatment of  patients with severely active ulcerative colitis 
(UC). But steroid free remission cannot be achieved in up 
to 40% of  these selected patients[1,2]. Thus, there is a need 
of  alternative treatment options. 
Etiology of  inflammatory bowel disease (IBD) is still 
unknown, but the pathogenesis is thought to comprise 
interaction between genetic factors, intestinal flora, and 
immunomediated tissue injury[3] Extravasation of  a large 
number of  granulocytes and macrophages into the mucosa 
plays a major role in the release of  proinflammatory 
cytokines[4,5], reactive oxygen derivatives[6-9], and degradative 
proteases[10]. Accordingly, immunosuppressive therapy has 
been introduced for refractory patients. Azathioprine/6-
mercaptopurine, cyclosporin, and tacrolimus are widely 
used at present. But drawbacks such as delayed efficacy, 
adverse events, and costs are currently still limiting the 
clinical success in severely ill patients and proctocolectomy 
is necessary in about one-third of  these patients. The 
search for a better treatment strategy has failed as yet. 
Trials with methotrexate, infliximab, and interferon have 
shown no convincing effects.
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In view of  the pathogenetic key role of  granulocytes 
and macrophages, it makes sense to focus on therapeutic 
goals here. A recently developed adsorptive carrier-
based granulocyte and monocyte apheresis device 
has demonstrated significant effects on inflammatory 
processes both in vivo and in vitro[11]. Preliminary data have 
shown promising therapeutic efficacy in IBD, rheumatoid 
arthritis, and other conditions[11]. Expanding on these 
findings, we have reported the results of  an open label 
study on the efficacy of  granulocyte apheresis treatment in 
severely ill patients with chronically active UC despite high 
doses of  systemic corticosteroids. 
MATERIALS AND METHODS
This was a prospective and open label trial investigating 
the efficacy, safety, and feasibility of  therapeutic apheresis 
in patients with active UC despite chronic intake of  
high doses of  systemic corticosteroids. The study was 
conducted in eight European gastrointestinal (GI) referral 
centers (Germany, Sweden, Italy, Spain) according to the 
Declaration of  Helsinki (as amended in Edinburgh) and 
the good clinical practice (GCP) guidelines. The study was 
approved by the “Ethikkommission der Ärztekammer 
Nordrhein”, Germany as well as local ethics committees 
of  the participating centers. All patients received materials 
in their own language and gave written consent. 
Patients were included if  they were aged between 18 
and 75 years and diagnosed with active disease (clinical 
activity index/CAI≥6 and ≤8, and endoscopic index/
EI>4)[12]. Additional inclusion criteria were as follows: 
patients who were dependent on steroids and relapsed 
despite continuous use of  steroids (a minimum total dose 
of  400 mg prednisone or equivalent within the last 4 wk, 
dose of  steroids was not changed 2 wk prior to the study), 
history of  at least one previous attack with an unsuccessful 
attempt to taper corticosteroids, immunosuppressants, and 
aminosalicylates were constant, 3 mo and 4 wk prior to the 
study, respectively. 
Exclusion criteria were patients with severe activity 
(CAI>8); pregnancy, nursing; arterial hypotension/
systolic pressure <11.97 kPa and/or diastolic pressure 
<8.645 kPa or hypertension (systolic pressure >23.94 kPa 
or diastolic pressure >15.96 kPa); serious renal, hepatic or 
cardiovascular disease; laboratory abnormalities such as 
neutrophils <1×109/L, platelets <100×109/L, hemoglobin 
<10 g/L, aPT >1.25 times upper range, aPTT >1.66 times 
upper normal range, AST or ALT >3 times upper normal 
range, total bilirubin >2.5 times upper normal range, 
creatinine >1.8 mg/L; allergy to heparin; viral infection 
within 4 wk prior to the study; positive stool microbiology; 
major bowel resection.
Study treatment
Each patient was intended to receive a total of  five 
apheresis sessions, each per week for 5 consecutive 
weeks. An apheresis session lasted for 60 min at a flow 
rate of  30 mL/min. Most treatments were performed 
in an outpatient clinic, partly in dialysis units and also in 
apheresis non-specialized settings.
The apheresis system used consists of  a pump with an 
integrated monitor (Adamonitor®, manufactured by Otsuka 
Electronics, Japan) and a single use polycarbonate column 
(Adacolumn®, CE-Mark; EC certificate GI030136676005, 
TUV) with a capacity of  about 335 mL, filled with 220 g 
cellulose acetate beads (about 35 000 pieces) of  2 mm in 
diameter (carriers) bathed in physiological saline and steam 
sterilized (manufactured by JIMRO, Japan). 
Concomitant medication according to inclusion criteria 
was permitted.
Study design
The aim of  this open label pilot study was to investigate 
the therapeutic effects of  a granulocyte adsorptive type 
apheresis system in patients with chronically active UC 
despite high doses of  corticosteroids. Clinical efficacy 
as well as feasibility and safety of  the procedure were 
evaluated.
Clinical examination and laboratory tests
Assessments were performed at the beginning and end of  
the study as well as after 1, 2, 3, 4, and 5 wk of  treatment. 
Clinical (clinical activity index, CAI) and endoscopic 
(endoscopic index, EI) findings were defined according 
to Rachmilewitz[12]. Endoscopies were performed at the 
beginning and the end of  study. Histology was reviewed 
by pathologists who were blinded to the study. Clinical 
remission was defined by a score of  CAI≤4, while clinical 
response was defined as a drop of  CAI≥3. Endoscopic 
remission was defined by an EI≤4, while endoscopic 
response was defined as a drop of  EI≥2. In addition, 
quality of  life was assessed according to the IBDQ scoring 
system[13]. IBDQ was not assessed in Italian patients 
(n = 5). Physician’s global assessment was asked for and 
the consumption of  steroids was noted.
Laboratory tests included a differentia l blood 
count, hemoglobin, hematocrit, fibrinogen, aPT, aPTT, 
ESR, CRP, orosomucoid, calcium, sodium, potassium, 
phosphorus, creatinine, BUN/urea, uric acid, bilirubin, 
total protein albumin, alpha1-antitrypsin, haptoglobin, 
alkaline phosphatase, AST, ALT, GGT, LDH, and standard 
urine analyses.
Statistical analysis
The primary objective of  this open multicenter study was 
to find the number of  patients achieving clinical remission 
(CAI≤4) at the end of  the treatment (wk 6). Because of  
the uncontrolled pilot characteristics of  the study, only 
descriptive statistical analyses were performed. Sample 
size was set at 35 patients. Two groups of  patients were 
analyzed. The intent-to-treat (ITT) population consisted 
of  all patients who experienced at least one complete (60 min) 
treatment of  apheresis. Only patients who fulfilled the 
protocol without major violations were included into the 
per-protocol (PP) population. Comparisons were made 
using Wilcoxon signed rank test.
    If  not otherwise mentioned, data were expressed as 
mean+SE. P<0.05 was considered statistically significant.
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Intent-to-treat analysis
At the end of  the treatment period (at wk 6) 13/35 patients 
(37.1%) achieved clinical remission (CAI≤4). Remission 
or clinical improvement was observed in 15/35 (42.8%) 
of  the patients. During a follow-up period (up to 4 
mo), the number of  patients achieving clinical remission 
increased to 20/31 patients (65%) (best estimate) (Figure 2). 
Except for doses of  steroids no other relevant changes in 
medication occurred during the follow-up. Four patients 
lost the follow-up. The clinical remission rate of  patients 
with concomitant immunosuppressants was 23% (3/13 
patients) at wk 6 and 54.5% (6/11 patients) at the end 
of  the follow-up. Figure 3 displays the course of  clinical 
(CAI) and endoscopic (EI) activity. Both indices dropped 
significantly between the beginning and end (at wk 6) of  
the treatment period.
Endoscopic remission (EI<4) was observed at wk 6 in 
10/35 (28.6%) patients. Mucosal healing (vulnerability of  
mucosa and mucosal damage scores) was improved in 19 
patients, unchanged in 13 patients and deteriorated in 3 
patients (P<0.001).
Between wk 0 and 6, changes in histology improved in 
14 (44%) patients, no change in 16 (50%) and deteriorated 
in 2 (6%) patients (P<0.002).
Quality of  life of  the 30 non-Italian patients (IBDQ) 
improved rapidly by 17 points within 3 wk of  treatment 
(P<0.01) and reached 162±6.4 points at wk 6 which was 
RESULTS
According to the inclusion criteria a total of  39 patients 
were recruited. Among the patients who underwent 
proctocolectomy, one patient received surgery before he 
started apheresis therapy because high grade dysplasia was 
found in the initial colonoscopy, the other two patients 
were operated upon because of  refractory disease at 
wk 6 during the follow-up period. Figure 1 displays the 
different analysis sets and reasons for exclusion. Biographic 
and clinical characteristics are listed in Table 1. Suitable 
venous access could not be accomplished in one patient. 
All the other patients who started treatment received 
five treatments with apheresis. A total of  176 apheresis 
procedures could be performed without major technical 
difficulties. The majority of  the patients (18/35) were 
treated in GI units, while 17/35 patients were treated in 
specialized dialysis units. Aphereses lasted for 60±3 min in 
90.3% of  the procedures and were prematurely stopped 
(50-55 min) in 1.7% procedures and the respective 
apheresis exceeded (65-91 min) in 8.0% procedures.
Recruited into
the study n = 39 
Intent-to-treat
Safety          Analysis
n = 35
Per-protocol-analysis
n = 34
 Protocol            –Significant increase of steroids
Violations      during the study n = 1
n = 1
No complete apheresis
– High grade dysplasia at entry colonoscopy
–Venous access impossible
–Change of CAI after screening evaluation to < 4
–Withdrawal of consent during the 1st  apheresis
Figure 1 Patients: Analysis sets and drop outs.
Wk 6         Follow-up till mo 4
(n  = 35)         (n  = 31)
Best estimate
Clinical remission
Clinical remission +
improvement of CAI
80
70
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40
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Figure 2 Patients (ITT analysis) in clinical remission or improved during a 4-mo 
follow-up period without additional apheresis therapy.
Table 1 Biographical and clinical characteristics of the patients 
studied (intent-to-treat population1)
Patients (ITT analysis)                                           n = 35
Age: median/range (yr)                                   35    (20-72)
Female n (%)                                                       10     (28.6)
Smoker n (%)                                                         2     (5.7)
Ex-smoker n (%)                                                       19   (54.3)
Disease: duration (mean+SE, yr) 7.2+0.8
Site of disease: extent n (%):
Proctosigmoiditis                                                        3  (8.6)
Left sided                                                                             9     (25.7)
Pancolitis                                                                           23  (65.7)
Pretreatment (all patients had steroids)
Aminosalicylates n (%)                                                       25   (74.4%)
Immunosuppressants n (%)                                   13   (37.1%)
1Note: Per-protocol population comprised all but one ITT patient.
Figure 3 Course of clinical and endoscopic activity indices (CAI, EI) throughout 
the apheresis treatment. aP<0.05 vs Et at wk 6, bP<0.01 vs Et at wk 5, dP<0.01 vs 
Et at wk 4, fP<0.05 vs Et at wk 3.
 Screening  Baseline   wk 2     wk 3     wk 4     wk 5      wk 6
CAI
EI12
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  8
  6
  4
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significantly (P<0.01) better than that at the beginning of  
the study (138.1±4.8 points).
Physician’s global assessment at wk 6 was ‘very much 
improved’ (11.4%), ‘much improved’ (37.1%), ‘minimally 
improved’ (25.7%), ‘no change’ (20.0%), ‘minimally worse’ 
(5.7%) and ‘much worse’ (0%).
Figure 4 displays the results of  blood cell counts and 
CRP serum concentrations between the beginning and 
wk 6 of  the study. With the exception of  the lymphocyte 
count all other numbers dropped, but none of  those 
changes reached statistical significance.
Consumption of  systemic steroids decreased significantly 
(P<0.05) throughout the whole treatment period. The 
median total dose of  systemic steroids was decreased from 
20.0 mg/d at baseline to 15.0 mg/d at wk 6. The means 
were 26.1+18.04 mg/d and 16.5+15.56 mg/d, respectively. 
At the end of  4-mo follow-up period, the median daily dose 
of  steroids was 6.5 mg (mean daily dose: 14.6+16.8 mg).
Per-protocol analysis
One patient of  the ITT patient group experienced several 
changes of  his dose of  steroids (increase or decrease >10 mg) 
throughout the study. He was, therefore, excluded from the 
per-protocol analysis. The patient did not achieve clinical 
remission but had clinical improvement.
Safety analysis
No unexpected adverse events occurred. The 35 patients 
included experienced a total of  46 adverse events (AEs) 
in 65 episodes recorded. Three events were serious: 
thrombosis of  the lower leg, worsening of  UC, and 
a significant drop of  hemoglobin which could not be 
explained despite extensive investigations (the patient 
recovered quickly). The causality was judged as unlikely, 
none and possible, respectively. All other AEs were judged 
as non-serious and mild or moderate. Ten had no causal 
relationship to the study treatment, 38 had a possible, and 
3 had a probable relationship. The three AEs probably 
related to the therapy were finger edema, right arm 
phlebitis, and paresthesia of  the left hand. All of  them 
were classified as mild. The 38 events judged as possibly 
related were headache, abdominal disorder, dysesthesia, 
dizziness, nausea, flush, muscle cramps, fatigue, vegetative 
dystonia, mood alteration, prostate inflammation, and 
urinary tract infection. They were judged as mild (28) or 
moderate (10). Those events classified as unlikely related to 
the study treatment were oral aphthae, vertigo, headache, 
common cold, cramps, thrombosis, arthralgia, meralgia, 
ankle swelling, and bronchopneumonia. Laboratory testing 
as mentioned in Methods did not reveal any significant 
alterations. 
DISCUSSION
Granulocyte apheresis application with five scheduled 
sessions strongly suggests efficacy in chronically active 
steroid refractory UC in the study reported here. A short 
treatment period of  5 wk resulted not only in significant 
clinical but also in significant endoscopic and histological 
improvements. Moreover, when aphereses were stopped, 
further beneficial effects could be observed. A follow-
up period of  4 mo demonstrated carryover effects of  the 
initial treatment leading to clinical remission in three out 
of  four patients. Apheresis treatment was safe and well 
tolerated.
These very good results must be critically seen in the 
light of  the open uncontrolled study design. Extracorporal 
treatment, apparently different from medicinal or surgical 
therapy, is a new method also for ‘experienced’ patients, a 
fact which may hold some placebo effects. Other studies 
demonstrated that the placebo effect is up to 30% in 
similar patient groups (e.g. 14) but to our knowledge, none 
of  those trials allowed ongoing intensive treatment (dose 
of  steroids, immunosuppressants) at entry to the study 
as in the present study. All patients kept on having their 
initial unsuccessful treatment with steroids and in part 
with immunosuppressants. Recent results of  other studies 
support our findings. Yamamoto et al[15] described 70% 
clinical remission in 30 patients with active distal UC and 
Naganuma et al[16] found a remission rate of  55% in either 
steroid refractory or dependent patients. Both trials used a 
similar treatment protocol.
The apheresis system is used to remove excess and 
activated leukocytes from peripheral blood. The release of  
proinflammatory cytokines in the peripheral blood such 
as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-
Baseline      wk 2          wk 3         wk 4         wk 5        wk 6
16
14
12
10
  8
  6
  4
  2
  0
A CRP (mg/L) B
Baseline   wk 2    wk 3     wk 4    wk 5    wk 6
90
80
70
60
50
40
30
20
10
  0
%
Neutrophils
Monocytes
Lymphocytes
Figure 4 Course of neutrophil, lymphocyte, and monocyte counts as well as CRP between the beginning and wk 6 of the study (numbers are given as means; no significant 
differences).
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1β), IL-6, and IL-8 is suppressed as well as the leukocyte 
adhesion molecules (L-selectin) and neutrophil adhesion to 
IL-1β-activated endothelial cells are downregulated[17-20]. In 
addition, it exerts antioxidant effects[21] and the production 
of  anti-inflammatory substances such as IL-1 receptor      
antagonist (IL-1ra), IL-10, and soluble TNF-α receptors 
I and II (sTNF-α RI and sTNF-α RII) is increased[22,23]. 
UC patients with high mucosal content of  IL-8mRNA 
responding well to granulocyte apheresis and mucosal 
IL-8mRNA can be significantly reduced[24]. Granulocyte 
apheresis seems also to modulate apoptosis[17]. These far 
reaching interventions on inflammatory immune reactions 
may explain the carryover effects of  granulocyte apheresis, 
when its application is stopped and standard treatment is 
continued. 
Adsorption techniques may lead to a decrease of  
circulating blood cells. Indeed peripheral granulocytes 
decrease significantly by 22% after a 60-min apheresis 
application in UC patients, but no granulocytopenia 
occurs[18]. Measurements of  pre- and post-column 
blood cell counts have demonstrated adsorption of  
65% of  granulocytes, 55% of  monocytes, and 2% of  
lymphocytes, but the number of  peripheral leukocytes 
does not fall below the normal level[19]. Flow cytometry 
has shown an increase in the number of  immature 
circulating granulocytes (CD 10 - neutrophils) which  
should be less proinflammatory[17]. The modest effect of  
apheresis on blood cell counts may prevent dangerous 
immunosuppressive adverse events seen in systemically 
acting immunosuppressants. 
The protocol of  our study prescribed 5-wk apheresis 
sessions with a duration of  60 min and a flow rate of  
30 mL/min, a procedure which is based on empiricism. 
Intensification of  this low exchange technique might 
create more rapid and/or more favorable therapeutic 
results. In a large trial in patients with rheumatoid arthritis 
the protocol here was compared to apheresis twice per 
week and no therapeutic advantage of  intense treatment 
could be observed[20]. In a small study in patients with UC, 
intensified apheresis revealed more rapid but not superior 
therapeutic effects[25]. As yet the most effective procedure 
remains unclear. Another way to intensify the effects of  
apheresis is to increase the exchange of  blood per time 
by augmenting the flow rate during the procedure. This 
may create technical difficulties. The easy technical success 
of  the protocol as it occurred in the present study is 
based on the low exchange protocol. Simple handling is 
a prerequisite of  the method for its introduction to non 
specialized (apheresis) units. 
In conclusion, granulocyte apheresis seems to be a very 
promising treatment, particularly in severely ill patients 
with UC. For patients refractory to standard therapies, it 
could offer an alternative which is safe and well tolerated. 
Controlled studies are urgently warranted. 
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